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Abstract
Background: A number of biomarkers have been proven potentially useful for their ability to indicate bone metastases (BM) in cancer 
patients. The aim of this study was to investigate the relative utility of a newly developed N-terminal propeptide of collagen type I 
(PINP) human serum assay for the detection of BM in cancer patients. This assay has a corresponding rat PINP assay which in the future 
might help in translational science between rodent and human trials.
Methods: Participants were 161 prostate, lung and breast cancer patients stratified by number of BM (Soloway score). PINP was assessed 
and correlated to number of BM. Additionally, the PINP marker was correlated to bone resorption of young (ALPHA CTX-I)- and 
aged bone (BETA CTX-I); number of osteoclasts (Tartrate-resistant acid phosphatase 5b, TRACP5B) and osteoclast activity (CTX-I/
TRACP5B).
Results: PINP was significantly elevated in breast- and prostate cancer patients +BM, compared to −BM (P , 0.001), however not in 
lung cancer patients. A strong linear association was seen between PINP and the number of BMs. Significant elevation of PINP was 
observed at Soloway scores 1–4 (,0 BM) compared with score 0 (0 BM) (P , 0.001). The correlation between bone resorption of 
young bone or aged bone and bone formation was highly significant in patients +BM and −BM (P , 0.0001).
Conclusions: Data suggest that the present PINP potentially could determine skeletal involvement in patients with breast or prostate 
cancer. Correlations suggested that coupling between bone resorption and bone formation was maintained in breast- and prostate 
cancer patients.
Keywords: biochemical markers, bone resorption, bone formation, osteoclastogenesis, breast cancer, prostate cancer, coupling
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Introduction
Several cancer types are able to metastasize to organs 
secondary to the primary tumor. Breast, prostate, and 
lung cancers are the primary tumors that most fre-
quently metastasize to the skeleton. A metabolically 
active bone metastasis (BM) exerts profound effects 
in the local bone micro-environment, the most sig-
nificant being the balance between bone resorption 
and bone formation -being either lytic or sclerotic 
 metastasis.1 This results in hypocalcaemia, which in 
turn leads to severe bone pain and lower quality of 
life. Early diagnosis and treatment of BM’s might 
mitigate these consequences.2
Currently, BM in cancer patients is mainly dia- 
gnosed by imaging techniques such as Techne-
tium-99 scintigraphy or x-ray.3,4 Imaging techniques 
are valuable diagnostic tools. However their accuracy 
in early diagnosis or feasibility in ongoing close moni-
toring of patients is limited.3 Even though scintigraphy 
can give quantitative information on skeletal “hot spots” 
containing BM’s, this assessment is expensive, inva-
sive, time-consuming, and exposes cancer patients to 
irradiation, limiting its use for monitoring purposes.4 
Easy-to-use and accurate diagnostic tools would be 
valuable supplements to imaging techniques.
Since biochemical markers of bone turnover can 
be assessed non-invasively, they could prove clini-
cally practical in providing additional systemic infor-
mation of bone turnover. A panel of markers may be 
selected to assess disease stages and skeletal sub-
type of the metastasis, and thereby provide essential 
information for choice of treatment. The use of bone 
turnover markers to detect the presence of BM’s is 
extensively discussed in the literature. Numerous 
biomarkers of bone resorption, formation, and osteo-
clastogenesis have been evaluated for their ability to 
indicate BM in cancer patients.5–17 Some biomarkers 
may prove more useful than others for the evaluation 
of BM’s. Several studies suggest that collagenous 
markers may be the most reliable markers in general 
for the presence of BMs.
Bone is a dynamic tissue which is continuously 
remodeled throughout life, not only to maintain cal-
cium homeostasis but also to repair micro- damage 
and thus maintain bone quality.18 This continu-
ous remodeling of bone involves cells that strive 
to achieve a coordinated and balanced resorption 
of old bone (osteoclasts) and those responsible for 
adequate formation of new bone (osteoblasts), in a 
local, coordinated and sequential manner referred 
to as coupling.19–22 When normal coupling occurs in 
healthy adult bones the amount of bone formed is 
equal to that resorbed.19–21,23,24 Uncoupling normally 
occurs when the balance between formation and 
resorption is dissociated, such as during normal skel-
etal growth, or in the pathogenesis of diseases such 
as osteopetrosis or osteoporosis,25,26 and turnover,18 
in some, but not all, osteopetrotic mutations.20,27 In 
postmenopausal osteoporosis there is an increase in 
both bone formation and bone resorption, however 
bone resorption exceeds bone formation leading to a 
continuous negative bone balance, bone fragility and 
increased risk of fractures.28,29
The aim of this study was to evaluate the ability of a 
newly developed bone formation serum assay (PINP) 
to detect the presence of BM in patients with breast, 
lung or prostate cancer. This ELISA assay  differs from 
other PINP assays by having a corresponding assay 
for the assessment of rat serum PINP thus  making 
it  possible to evaluate the same epitope30 in both 
a preclinical cancer model and in clinical studies. 
 Furthermore, we aimed to investigate whether  coupling 
existed between bone formation, bone  resorption, 
and the number of osteoclasts. These analyses were 
performed by  correlating PINP data, indicating bone 
formation, to the well-established C-telopeptide of 
collagen type I bone resorption markers ααCTX-I31 
(of young bone) and ββCTX-I32 (of aged bone), and 
TRACP5B as an index for osteoclast numbers.33–35
Materials and Methods
Patients and study design
The study design has been published previously.15 
Briefly, the study included 90 breast cancer patients 
(45 +BM and 45 −BM), 30 lung cancer patients 
(16 +BM and 14 −BM) and 42 prostate cancer 
patients (25 +BM and 17 −BM) that were referred to 
the Cancer Institute Hospital, Tokyo, Japan, between 
 October 2002 and April 2004. All patients underwent 
bone scans using a radionuclide (Technetium-99m), as 
well as computer tomography (CT) and/or magnetic 
resonance imaging (MRI) to verify and quantify the 
presence of BMs. All patients with skeletal complica-
tions were newly diagnosed and none had received 
therapies known to influence bone turnover in the 
previous 2 years prior to entry to the study. One breast 
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cancer patient had also been diagnosed with Paget’s 
disease and was excluded from the analysis.
All participants signed approved written consent 
and the study was performed in accordance with the 
Helsinki Declaration II and Standards of Good  Clinical 
Practice. The Local Ethical Committee approved the 
study protocol.
Severity of metastatic bone disease 
(Soloway score)
The number of BM was recorded and the skeletal 
load was graded, as previously proposed by Soloway 
et al. Briefly, Soloway 0 refers to patients without 
BM, Soloway 1 to patients with fewer than 6 BM, 
Soloway 2 to patients with 6–20 BM, Soloway 3 
to patients with more than 20 but less than a “super 
scan” defined involvement of more than 75% of the 
ribs, vertebrae, and pelvic bones; and Soloway 4 to 
patients with a “super scan”.36
Quantification of bone resorption  
by serum PInP
Serum samples were collected from all patients and 
stored at −40 °C until analysis. The concentration of 
PINP fragments was measured by the newly developed 
competitive ELISA assay for human N-terminal pro-
petide of collagen type I (Nordic Bioscience,  Herlev, 
Denmark). The assay was run using 20 µl undiluted 
serum samples in a one-step ELISA 1 hour at 4 °C 
using a horse radish labeled monoclonal antibody 
against a 10 amino acid sequence in the N-terminal 
pro-peptide of collagen type I.30 Mean intra-variation 
on 10 independent runs was 4.4% on double determi-
nations. Mean inter-variation on 10 independent runs 
was 5.4% on double determination. Dilution recovery 
was 90%–114% on 10 normal serum samples repre-
senting the entire range of the standard curve.30
Bone resorption and number  
of osteoclasts
Data on the collagen type I bone resoption mark-
ers ββCTX-I32 (assessing resorption of aged col-
lagen type I) and ααCTX-I31 (resorption of newly 
synthesized collagen type I) and the marker for the 
number of osteoclasts (TRACP5b) have been pub-
lished previously by our group15 and these data were 
used for correlations to the bone formation marker, 
PINP, detected in serum. The correlation between the 
CTX-I/TRACP5b ratio, and PINP, was used to indi-
cate resorption activity per osteoclasts versus bone 
formation.
Statistical analysis
The values of each of the biochemical markers were 
logarithmically transformed to obtain normality. 
Comparisons between the level of PINP in patients 
with different cancer types without BM was per-
formed by analysis of variance (ANOVA) using the 
General Linear Models Procedure (GLM). The same 
statistical procedure was used for comparison of 
PINP levels in patients without and with BM for each 
cancer type. In the comparison of the PINP levels for 
each Soloway score against the level in patients with-
out metastasis, the Dunnett’s adjustment of the level 
of significance was employed to correct for multiple 
comparisons. Correlations between the biochemi-
cal markers were determined using Spearmans Rho. 
 Differences and associations were considered statisti-
cally significant if P , 0.05. GRAPH PAD PRISM 5 
(Graph Pad Software, La Jolla, CA, USA) was used 
for calculations.
Results
PInP related to bone cancer type
Demographics of 161 cancer patients stratified 
according to cancer type and the presence or absence 
of BM have previously been reported.15 There were 
no statistically significant differences in age and BMI 
between patients with or without BM.
Figure 1 shows the mean values of serum PINP in 
patients stratified according to cancer type and pres-
ence or absence of BM. There was a significantly 
increased level of PINP, indicating increased bone 
formation, in breast and prostate cancer patients with 
BM compared with those without BM. However, 
PINP was not able to determine the presence of BM 
in lung cancer patients.
PInP related to the extent of metastatic  
bone disease
Since this assay carried little value in diagnosing BM in 
lung cancer patients, this subpopulation was excluded 
from further analyses. Accordingly, data from breast 
and prostate cancer patients were pooled together 
for subsequent analyses (n = 132). The  demographic 
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data for patients was stratified according to Soloway 
score. No linear associations were found between 
Soloway score and the demographic characteristics 
of patients.15
Figure 2 shows associations between  Soloway 
score and the mean PINP values. The marker  indicated 
significant linear increases with advancing severity 
of the metastatic involvement of the skeletal system. 
PINP was highly significantly increased at all Solo-
way scores 1, 2, 3 and 4 compared with Soloway 
score 0 (ie, no BM) (P , 0.001).
The coupling between bone formation  
and bone resorption in breast and prostate 
cancer patients
Patients with prostate or breast cancer were pooled 
and stratified by +BM and −BM for correlation cal-
culations. Correlations were performed using both the 
ααCTX-I resorption marker as a measure of osteo-
clast resorption of newly synthesized collagen type I 
(Fig. 3) and the ββCTX-I resorption marker as a mea-
sure of osteoclast resorption of aged synthesized col-
lagen type I37 (Fig. 4). A significant correlation was 
observed for all our correlation tests (P , 0.0001) in 
both +BM patients (Figs. 3A and 4A) and −BM patients 
(Figs. 3B and 4B) except for ββCTX-I/TRACP5b 
ratio vs. PINP in patients with BM. Data indicated that 
bone formation, as assessed by PINP vs. resorption of 
young or old bone (ααCTX-I or ββCTX-I); bone for-
mation (PINP) vs. number of osteoclasts (TRACP5b); 
 resorption of young or old bone (ααCTX-I or 
ββCTX-I) vs. number of osteoclasts (TRACP5b) and 
the activity of osteoclasts (ααCTX-I or ββCTX-I/
TRACP5b) vs. bone formation (PINP) all are associ-
ated in breast and prostate cancer patients both with or 
without BM. In patients with BM Spearman correla-
tions were strongest when using the resorption marker 
ααCTX-I rather than ββCTX-I.
Discussion
We evaluated a newly developed PINP assay in a clin-
ical study of breast and prostate cancer patients with 
and without BM. Furthermore, we investigated the 
coupling between bone resorption and bone forma-
tion related to number of osteoclasts. Only one small 
study on coupling in prostate cancer patients has 
previously been conducted, which included admin-
istration of gonadotropin-releasing hormone agonist 
treatment.38 In these patients coupling between bone 
resorption and formation was observed.
Our main findings were: 1) Elevated levels of this 
serum PINP assay was found in prostate- and breast 
cancer patients with BM compared to patients with-
out BM, however not in lung cancer patients; 2) This 
PINP assay was increased according to number of BM 
when stratified by the Soloway score with significant 
increase at score 2, 3 and 4; 3) There was significant 
correlations between bone formation (PINP), resorp-
tion (CTX-I) and number of osteoclasts (TRACP5B) 
in prostate- and breast cancer patients with BM.
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Figure 1. Bone formation (PInP) marker levels in 161 breast, lung and 
prostate cancer patients stratified by cancer type and presence (+BM) or 
absence of bone metastasis (−BM). 
note: results shown are geometric mean ± SeM.
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Figure 2. Bone formation (PInP) marker levels in 132 breast and prostate 
cancer patients stratified according to the extent of metastatic bone dis-
ease described by the Soloway score 0 (−BM), and 1–4 (+BM). number 
of patients within each Soloway score: 0 (n = 45); 1 (n = 20); 2 (n = 13); 
3 (n = 7) and 4 (n = 5).
notes: results shown are geometric mean ± SeM. ***P , 0.001 indi-
cated highly significant elevated level in +BM patients compared to −BM, 
ns = non significant elevation in +BM patients as compared with −BM.
PInP is related to bone metastases in cancer patients
Biomarkers in Cancer 2011:3 19
The occurrence of tumor cells in bone tissue have 
a strong impact on the mechanisms of bone turnover 
due to the secretion soluble factors such as  hormones, 
cytokines and growth factors which directly or indi-
rectly stimulate osteoclast and osteoblast proliferation 
and function.1,39 This cell-cell interaction is com-
monly referred to as the vicious cycle. Breast cancer 
metastases are predominately osteolytic (70%–85%)39 
whereas the majority of prostate cancer metasta-
ses are osteoblastic (65%)40 although mixed lesions 
exists in both cancer types.41 These differences pro-
vide the rationale for investigating different biomark-
ers in evaluating BM in patients with  different types 
of  cancer. The results may be useful for tailoring 
 treatment for individual patients.
Comparison of PInP assays  
and their relation to bone metastases
In the present paper we evaluated a newly devel-
oped PINP assay for the detection of BM in prostate-, 
lung- and breast cancer patients. This human serum 
PINP assay differs from other PINP assays42–44 by 
the fact that it has a parallel PINP assay for30 corre-
sponding epitope in the rat PINP sequence, and thus 
offers potential value in translational science between 
rat cancer models and human studies. We found that 
the PINP levels assessed by this human serum PINP 
assay, was significantly higher in patients with BM 
than in patients without BM in the case of prostate 
and breast cancers but not lung cancer. There was 
however a trend towards higher levels in lung  cancer 
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patients with BM compared to without BM so the 
lack of difference may be due to the low number of 
lung cancer patients.
Data stratified according to the Soloway score 
indicated that the levels assess by this PINP assay was 
correlated to the number of BM. Levels were highly 
significantly elevated at all Soloway scores, indicat-
ing that this assay is very sensitive for the detection of 
BM. However, we do not have data available to deter-
mine whether it is more sensitive that scintigraphy.
By the use of different PINP assays, other groups 
have evaluated PINP in relation to bone metastases.45–55 
In relation to our study a group showed that the lev-
els assessed by another PINP assay were significantly 
elevated in breast cancer patients with BM compared 
to those without BM, and correlated to the number 
of BM’s.55 A PINP assay was evaluated in 64 pros-
tate cancer patients stratified by −BM; −BM/+lymph 
node metastases or +BM. Here PINP was elevated in 
the −BM/+lymph node metastases and +BM groups 
when compared to the −BM group.56 Interestingly, PINP 
was even elevated 8 months prior to detection of the first 
BM by scintigraphy, indicating that PINP is a powerful 
marker for very early diagnosis of BM which might not 
be detected by other means. Similar findings have been 
presented by Koizumi et al57 who showed PINP was 
elevated in prostate cancer patients with BM compared 
to those without BM. Nevertheless, PINP was the best 
discriminator, among three markers, of the extent of 
disease. Finally, Jung et al28 who analyzed 10 different 
serum markers and found that PINP was significantly 
elevated in patients with BM compared to without BM. 
All these findings correspond to our evaluation of this 
newly developed human serum PINP assay.
PInP compared to other bone formation 
marker for the detection of BM
Other markers of bone formation such as bone alka-
line phosphates (BALP), osteocalcin (OC), have been 
evaluated for their ability to describe bone metasta-
ses indicating that some bone formation markers are 
and some are not elevated in prostate- and breast can-
cer patients.58–60 Recently, a group demonstrated that 
BSAP was elevated in prostate cancer patients with 
BM and correlated to the Extent of disease (EOD), 
whereas OC did not.60 Similar data for OC have been 
published by Hegele A et al59 showing that OC was 
not elevated in  prostate cancer patients with BM. It 
may be  difficult to directly compare different bone 
formation markers since they all are of a different 
nature. PINP is a  collagenous marker; OC is a non-
collagenous marker;61 bone alkaline phosphatase is 
an enzyme found on the surface of osteoblasts.62 The 
expression of the collagen type I gene is known to 
be expressed prior to the alkaline phosphatase genes 
and alkaline phosphatase prior to the OC genes indi-
cating that collagen type I derived markers may be 
most helpful for early  detection of BM.63
Different assays assessing different epitopes of 
the same bone formation protein may further compli-
cate the picture. Thus, several statements in the bone 
field have been made with regards to the relevance 
of assessing either the monomeric or trimeric form 
of the PINP peptide.64,65 Further research is needed 
to understand why measurements of the same protein 
by different assessment technologies produce differ-
ent outcomes, and the possible pathological rationale 
for the discrepancies.
Coupling between osteoclasts  
and osteoblasts
Even in BM of the osteolytic nature, highly increased 
levels of bone formation parameters have been iden-
tified in the vicious cycle.1,39,66 This emphasizes 
that more research into the coupling between bone 
 resorption and bone formation may be important in 
detecting different types of BM.
Interestingly, the coupling between bone resorp-
tion and bone formation was maintained in these 
prostate- and breast cancer patients with BM or with-
out BM when analyzed separately with no differentia-
tion between cancer types (data not shown). Thus we 
pooled the data to increase the statistical power. Bone 
formation was significantly related to bone resorption 
and the number of osteoclasts; in the same manner 
bone resorption was significantly related to number 
of osteoclasts.
ααCTX-I as a resorption marker
Levels of ααCTX-I may possibly originate mainly 
from bone metastases due to their local high bone 
turnover characteristic, thus generating large 
 quantities of newly formed collagen type I matrix. 
Viewing the Spearman Rho coefficients it was note-
worthy that in patients with BM, a higher correlation 
was observed between PINP/TRACP5b (r = 0.84) 
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and PINP/ααCTX-I (r = 0.84) than was observed for 
ααCTX-I/TRACP5b (r = 0.76). This indicates that 
the number of osteoclasts and bone formation is more 
tightly coupled than the number of osteoclasts and 
bone resorption. Furthermore, the mean resorption of 
young bone per osteoclast (ααCTX-I/TRACP5b) was 
well correlated to PINP in patients with BM (r = 0.81) 
indicating that the resorption activity per osteoclast 
was not elevated in these patients. However, further 
investigations are needed for such a conclusion and 
should be regarded as speculation. In patients with-
out BM a similar picture was seen. Spearman correla-
tions were similar between all remodeling parameters, 
indicating that all were just as tightly coupled with 
regards to resorption of young bone.
ββCTX-I as a resorption marker
Levels of ββCTX-I may originate mainly as a mean 
of the total turnover of the skeleton due to the high 
amount of isomerized collagen type I in normally 
remodeled bone matrix. The Spearman Rho coeffi-
cients showed that ββCTX, PINP and TRACP were 
just as strongly correlated in patients with and with-
out BM. However, the mean resorption activity on 
aged bone per osteoclast was not correlated to bone 
formation in patients with bone metastases also indi-
cating that bone formation is more tightly coupled to 
number of osteoclasts and not their activity in patients 
with bone metastases.
These data are somewhat in alignment with 
research suggesting that it is rather the presence of 
osteoclasts and not resorptive activity that is important 
for bone formation.34 Compelling evidence for this is 
the fact that, in the normal adult skeleton, bone for-
mation is almost exclusively initiated in areas having 
undergone resorption19–22,67 indicating local signaling 
events between osteoclasts and osteoblasts. Consis-
tent with this, the number of nuclei in osteoclasts has 
been shown to correlate to the number of osteoblasts.68 
Recently osteoclasts themselves were demonstrated to 
secrete bone anabolic signals.69 This also led to specu-
lation that resorbing osteoclasts do not always secrete 
the anabolic signal70 implying that the anabolic sig-
nal is not derived exclusively during resorption of the 
bone matrix. Further strengthening this new view of 
the coupling between bone resorption and bone for-
mation, was that bone resorption was less correlated 
to bone formation in cancer patients overall.
Limitations
An increasing number of publications have shown 
that biomarkers are potential candidates for a more 
dynamic evaluation of BM in breast- and pros-
tate cancer patients.5–17 However, since biomarkers 
often are assessed systemically they do not neces-
sarily reflect the local environment of a BM site, but 
rather are means of the total bone remodeling in the 
entire  skeleton. They also do not necessarily reflect 
local coupling between bone formation and bone 
 resorption, but throughout the body.
There are important differences in the pathogenesis 
of osteolytic bone metastases and osteoblastic bone 
metastases,1,39–41 that most likely affect coupling between 
bone resorption and bone formation. Further investiga-
tions are needed to understand how the two different 
types of metastases affect coupling. The power of this 
study was not high enough to add to that discussion.
Another limitation is that this was a cross-sectional 
study and the statistical analysis was based on an 
assumption that the individual variation in biomarker 
levels in patients was low. Future analysis should be 
performed in a longitudinal study.
In conclusion, the present study evaluated a newly 
developed human serum PINP and its ability to describe 
bone metastases. Furthermore, it provided additional 
evidence that PINP markers may be useful for obtain-
ing valuable systemic information about the develop-
ment of BM in breast- and prostate cancer patients.
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